ArticleScientific reports2026
Developing a fully automated imaging biomarker for HCC risk assessment via MRI-based tumor segmentation and EPM.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
16 authors.
Funding
Abstract
This study investigates the feasibility of using automated tumor segmentation as the region of interest for early detection of hepatocellular carcinoma (HCC) using magnetic resonance imaging (MRI). Enhancement Pattern Mapping (EPM) is used as a voxel-wise imaging biomarker within the region of interest once segmentations are generated. We implement PocketNet, a lightweight convolutional neural network, to segment liver tumors and evaluate performance. To contextualize model accuracy, we estimate the theoretical upper bound of segmentation performance through inter-observer comparisons of manual annotations. Imaging-derived features from automated segmentations are analyzed using XGBoost to assess their predictive value. Results show that automated segmentation approaches upper-bound performance for larger tumors but underperforms on smaller lesions. However, EPM features derived from automated masks demonstrate comparable predictive power to those from manual segmentations, indicating that the EPM features are stable with respect to segmentation inaccuracies. Results demonstrate that a fully automated imaging biomarker may be developed as a clinical utility for HCC risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.